BLK
BlackRock, Inc.
BLK's fundamentals are mixed, but it looks expensive: trading at 28x earnings, above its usual 22x.
BMA
Banco Macro S.A.
There isn't enough reported data to score BMA yet.
BLK Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| N/A | |
| N/A |
BLK's revenue and profitability are currently healthy. Free cash flow and net leverage aren't meaningful measures for financial services companies like BLK.
BMA Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Stable | |
| N/A | |
| N/A |
BMA's profitability is currently stable. There isn't enough data to rate its revenue. Free cash flow and net leverage aren't meaningful measures for financial services companies like BMA.
BLK PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 19x | $848 | -30% |
| Fair | 22x | $973 | -20% |
| Expensive | 26x | $1,149 | -5.5% |
| Current | 28x | $1,217 | — |
Historical ranges are pointers, not guarantees.
BLK's PE is in its expensive range at 28x.
BMA PE Valuation
BMA has no meaningful PE right now: it lost money over the past year.
BLK Forward outlook
There aren't enough analyst estimates for BLK to show an outlook.
BMA Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| High |
Analysts expect strong earnings and revenue growth for BMA, with profitability improving.
BLK Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | $43.87 | +11% |
| Q2 2026 | $41.73 | -0.4% |
| Q1 2026 | $39.73 | -4.7% |
| Q4 2025 | $35.31 | -17% |
| Q3 2025 | $39.42 | -2.7% |
| Q2 2025 | $41.89 | +4% |
| Q1 2025 | $41.69 | +5.9% |
| Q4 2024 | $42.53 | +16% |
BLK has the stronger earnings trend. Trailing diluted EPS is up 11% for BLK versus BMA down 59%.
BMA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2025 | $2.98 | -59% |
| Q2 2025 | $4.23 | -35% |
| Q1 2025 | -$0.48 | -104% |
| Q4 2024 | $3.45 | -51% |
| Q3 2024 | $7.21 | +226% |
| Q2 2024 | $6.52 | +198% |
| Q1 2024 | $11.38 | +1735% |
| Q4 2023 | $7.10 | +1009% |
BMA's earnings per share have fallen from their peak: $2.98 over the past year, against $11.38 in early 2024.
BLK Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $7.8B | +19% |
| Q2 2026 | $7.1B | +31% |
| Q1 2026 | $6.7B | +27% |
| Q4 2025 | $7B | +23% |
| Q3 2025 | $6.5B | +25% |
| Q2 2025 | $5.4B | +13% |
| Q1 2025 | $5.3B | +12% |
| Q4 2024 | $5.7B | +23% |
BMA has the stronger quarterly revenue trend. Revenue is up 19% for BLK versus up 31% for BMA.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 30% | 0 points |
| Q2 2026 | 35% | +2.8 points |
| Q1 2026 | 42% | +9.8 points |
| Q4 2025 | 24% | -13 points |
| Q3 2025 | 30% | -8.6 points |
| Q2 2025 | 32% | -5.5 points |
| Q1 2025 | 32% | -3.6 points |
| Q4 2024 | 37% | +2.3 points |
BLK has the edge over BMA on profitability, with a higher operating margin.
BMA Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $950.1M | +4.1% |
| Q1 2026 | $1.2B | +70% |
| Q3 2025 | $933.9M | +30% |
| Q2 2025 | $912.7M | +16% |
| Q1 2025 | $725M | -66% |
| Q4 2024 | $970.7M | -44% |
| Q3 2024 | $719.9M | -46% |
| Q2 2024 | $789.5M | -29% |
BMA's revenue is recovering but still below its 2024 peak: $950M last quarter, up 31% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 22% | +15 points |
| Q1 2026 | 11% | -0.1 points |
| Q3 2025 | -2.6% | -14 points |
| Q2 2025 | 17% | +59 points |
| Q1 2025 | 7.2% | -10 points |
| Q4 2024 | 11% | -17 points |
| Q3 2024 | 11% | +8 points |
| Q2 2024 | -41% | -55 points |
BMA's operating margin was 22% last quarter, up 15 points from the same quarter a year ago, near the top of its range since 2019.
BLK Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $2.6B | +95% |
| Q2 2026 | $1.1B | -12% |
| Q1 2026 | -$1.1B | +$120M |
| Q4 2025 | $2.1B | -15% |
| Q2 2025 | $1.3B | -6.1% |
| Q1 2025 | -$1.2B | -$734M |
| Q4 2024 | $2.5B | +35% |
| Q2 2024 | $1.4B | +47% |
BMA has the stronger cash trend. Its trailing FCF is up 207% versus its history, compared with BLK at up 20%.
BMA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $372.3M | +$984.4M |
| Q1 2026 | $384.5M | +$1B |
| Q3 2025 | $304.5M | -63% |
| Q2 2025 | -$612.1M | -271% |
| Q1 2025 | -$616.8M | -10886964% |
| Q4 2024 | -$353.2M | -$232.5M |
| Q3 2024 | $818.8M | +$896.2M |
| Q2 2024 | $357M | +$365.4M |
BMA's free cash flow was $449M over the past year, up 118% from the year before. Free cash flow isn't a meaningful measure for financial services companies like BMA.
BLK Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.1% | -148K shares |
| 1 year | -0.4% | -677K shares |
| 3 years | +9.3% | +14M shares |
| 5 years | +6.2% | +9.6M shares |
| Available history | +4.4% | +7M shares |
BLK has the edge over BMA on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2025 | $396M |
| Q1 2025 | $657M |
| Q4 2024 | $386M |
| Q2 2024 | $519M |
| Q1 2024 | $634M |
| Q4 2023 | $384M |
| Q3 2023 | $396M |
| Q2 2023 | $383M |
BMA Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.1% | -38K shares |
| 1 year | -0.1% | -40.3K shares |
| 3 years | -0.1% | -40.3K shares |
| 5 years | -1.2% | -804K shares |
| Available history | -0.1% | -38.8K shares |
BMA has 64M diluted shares, about the same as a year ago.
| Quarter | Spent |
|---|---|
| Q2 2026 | — |
| Q1 2026 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | — |
| Q3 2024 | — |
| Q2 2024 | — |
BLK Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -0.0x | Net Cash |
| Q2 2026 | 0.2x | Very low |
| Q1 2026 | 0.3x | Very low |
| Q4 2025 | 0.2x | Very low |
| Q3 2025 | 0.3x | Very low |
| Q2 2024 | 0.2x | Very low |
| Q1 2024 | 0.3x | Very low |
| Q4 2023 | 0.1x | Very low |
BLK has more cash than debt. Net leverage isn't a meaningful measure for financial services companies like BLK.
BMA Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2025 | -3.1x | Net Cash |
| Q2 2025 | -2.0x | Net Cash |
| Q1 2025 | -57.5x | Net Cash |
| Q4 2024 | -4.4x | Net Cash |
| Q3 2024 | -2.8x | Net Cash |
| Q2 2024 | -1.3x | Net Cash |
| Q1 2024 | -0.4x | Net Cash |
| Q4 2023 | -1.5x | Net Cash |
BMA has more cash than debt. Net leverage isn't a meaningful measure for financial services companies like BMA.
BLK Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 64.5 | Neutral |
| Stochastic | 79.0 | Neutral |
BLK's weekly RSI is 64 (neutral) and its Stochastic is 79 (neutral).
BMA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 32.6 | Neutral |
| Stochastic | 4.0 | Oversold |
BMA's weekly RSI is 33 (neutral) and its Stochastic is 4 (oversold).
BLK PE vs Financial Services Sector
| Metric | BLK | Sector median | Relative |
|---|---|---|---|
| PE | 28x | 13x | 113% above |
| PE % | 97 | 63 | 34 pts above |
BLK is trading at 28x earnings, a 113% premium to the Financial Services sector's median of 13x.
BMA PE vs Financial Services Sector
BMA has no meaningful PE right now: it lost money over the past year.
BLK Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,128.0 | 7.9% above |
| 20 week MA | $1,108.9 | 9.7% above |
| 50 week MA | $1,071.6 | 14% above |
| 100 week MA | $1,051.1 | 16% above |
| 200 week MA | $914.1 | 33% above |
BLK has the edge over BMA on trend strength, trading above more of its moving averages.
BMA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $62.7 | 12% below |
| 20 week MA | $75.0 | 26% below |
| 50 week MA | $80.5 | 31% below |
| 100 week MA | $79.3 | 30% below |
| 200 week MA | $59.4 | 6.9% below |
BMA is in a downtrend: it's below all five of its weekly moving averages, and 6.9% below its 200-week average.
BLK Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $503.0 | $707.2 | +41% |
| 2021 | $707.2 | $913.9 | +29% |
| 2022 | $913.9 | $703.9 | -23% |
| 2023 | $703.9 | $811.8 | +15% |
| 2024 | $811.8 | $1,044.2 | +29% |
| 2025 | $1,044.2 | $1,088.1 | +4.2% |
| 2026 YTD | $1,088.1 | $1,216.6 | +12% |
BLK has the edge over BMA on returns for 2026, with the stronger performance.
BMA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $36.4 | $15.6 | -57% |
| 2021 | $15.6 | $14.6 | -6.6% |
| 2022 | $14.6 | $15.8 | +8.9% |
| 2023 | $15.8 | $28.7 | +81% |
| 2024 | $28.7 | $100.2 | +249% |
| 2025 | $100.2 | $91.4 | -8.8% |
| 2026 YTD | $91.4 | $55.2 | -40% |
BMA's yearly returns have swung widely, from +249% in 2024 to −57% in 2020. It's down 40% so far in 2026.